NAGE
Niagen Bioscience, Inc. Common StockNAGE
NAGE
About: Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
Employees: 104
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1,185% more call options, than puts
Call options by funds: $1.89M | Put options by funds: $147K
133% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 15
48% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 33
44% more capital invested
Capital invested by funds: $119M [Q4 2024] → $172M (+$52.7M) [Q1 2025]
13% more funds holding
Funds holding: 123 [Q4 2024] → 139 (+16) [Q1 2025]
2.58% more ownership
Funds ownership: 29.44% [Q4 2024] → 32.02% (+2.58%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$16
68%
upside
Avg. target
$19.50
105%
upside
High target
$23
141%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Canaccord Genuity Susan Anderson | 68%upside $16 | Buy Maintained | 10 Jun 2025 |
Roth Capital Sean McGowan | 141%upside $23 | Buy Maintained | 6 Jun 2025 |
Financial journalist opinion
Based on 3 articles about NAGE published over the past 30 days
Neutral
Business Wire
1 week ago
Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, August 6, at 4:30 p.m. ET to discuss its financial results for the second quarter 2025, which ended June 30, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on W.
Neutral
Business Wire
2 weeks ago
Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the inaugural hotel debut of Tru Niagen® as an in-room amenity at the Equinox Hotel New York, and Niagen IV, now available at the hotel's spa through NutriDrip. Rob Fried, CEO of Niagen Bioscience, remarked, “Our partnership with Equinox Hotel and NutriDrip underscores our c.
Neutral
Business Wire
3 weeks ago
Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson's Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced it has entered into a worldwide exclusive commercial license agreement with the Haukeland University Hospital, Bergen, Norway. The agreement secures exclusive rights to a body of proprietary intellectual property, know-how, and data. These data are expected to support future.
Positive
Seeking Alpha
1 month ago
Niagen Biosciences: Anti-Aging Market Leader And Prime Beneficiary Of Long-Term Demographic Trends
NAGE is a leader in the growing NAD+ supplement market, benefiting from rising health and longevity trends and strong brand awareness with its flagship Tru Niagen product. Analyst estimates for 2025 remain too low; further upside revisions look possible based on our alternative data channel checks. Our DCF valuation suggests at least 20% upside as a standalone company, and even more if viewed through the lens of a potential acquirer.
Neutral
Business Wire
1 month ago
Niagen Bioscience to Participate at the Roth 15th Annual London Conference
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate at the Roth 15th Annual London Conference, which will be held at the Four Seasons Hotel London at Park Lane in London, UK on June 24-26, 2025. Niagen Bioscience CFO, Ozan Pamir, will attend in-person one-on-one meetings with institutio.
Neutral
Business Wire
1 month ago
Niagen Bioscience to Participate in the BIO 2025 International Convention
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced its participation in the 2025 BIO International Convention, taking place June 16–19, 2025, in Boston, Massachusetts. Hosted by the Biotechnology Innovation Organization (BIO), the BIO International Convention is the world's largest and most influential biotechnology event, c.
Positive
Seeking Alpha
1 month ago
Niagen Bioscience: High Conviction, High Expectations
Niagen Bioscience's stock price is breaking out with strong fundamentals, proprietary IP, and a leadership position in the NAD+ longevity market. Revenue and margins are rising, driven by Tru Niagen e-commerce and pharma-grade injectables, with operating leverage and efficient marketing boosting profitability. Valuation is rich, reflecting high expectations for continued growth and clinical pipeline success, but execution risk is elevated at these multiples.
Neutral
Business Wire
1 month ago
Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, shares positive results from a clinical study published in the peer-reviewed journal Aging Cell, by a team led by Masaya Koshizaka, M.D., Ph.D., Associate Professor, and Koutaro Yokote, M.D., Ph.D., MBA, President of Chiba University, both of the Center for Preventive Medical Sciences, Chib.
Neutral
Business Wire
1 month ago
Niagen Bioscience to Present at Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #InvestorRelations--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference. Mr. Fried is scheduled to participate in a fireside chat on Monday, Jun 9, from 2:15 p.m. to 2:50 p.
Neutral
Seeking Alpha
2 months ago
Niagen Bioscience, Inc. (NAGE) Q1 202 Earnings Call Transcript
Niagen Bioscience, Inc. Q1 2025 - Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Wesley Yu - VP of Finance Rob Fried - CEO Ozan Pamir - CFO Andrew Shao - SVP, Scientific & Regulatory Affairs Conference Call Participants Ram Selvaraju - H. C. Wainwright Mitch Pinheiro - Sturdivant & Company Sean McGowan - ROTH Capital Partners Matt Dain - Tieton Capital Management Susan Anderson - Canaccord Genuity JP Mark - Farmhouse Equity Research Operator Ladies and gentlemen, thank you for standing by, and welcome to Niagen Biosciences Inc. First Quarter of 2025 Earnings Conference Call.
Charts implemented using Lightweight Charts™